BMO Capital Upgrades Nektar Therapeutics (NKTR) to Outperform
Tweet Send to a FriendGet Alerts NKTR Hot Sheet
Price: $9.27 -0.43%
Rating Summary:
3 Buy, 1 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
3 Buy, 1 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade NKTR Now!
BMO Capital upgrades Nektar Therapeutics (Nasdaq: NKTR) from Market Perform to Outperform. Price target $12.
To see more analyst ratings on NKTR Click Here.
Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.
To see more analyst ratings on NKTR Click Here.
Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- Janney Montgomery Scott Upgrades Stellus Capital (SCM) to Buy
- Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
Create E-mail Alert Related Categories
UpgradesRelated Entities
BMO Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
